IGC
IGC Pharma, Inc.
IGC trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over IGC overall, supported by stronger fundamentals and lower modeled downside.
IGC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
IGC's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
IGC PE Valuation
IGC has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
IGC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect IGC's revenue to grow, with its earnings and profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
IGC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.08 | $0.00 |
| Q2 2026 | -$0.08 | $0.00 |
| Q1 2026 | -$0.07 | +$0.02 |
| Q4 2025 | -$0.06 | +$0.06 |
| Q3 2025 | -$0.08 | +$0.11 |
| Q2 2025 | -$0.08 | +$0.13 |
| Q1 2025 | -$0.09 | +$0.13 |
| Q4 2024 | -$0.12 | +$0.13 |
IGC is still losing money, but far less than before: $0.08 per share over the past year, against $0.32 at its worst in mid-2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over IGC on earnings quality, reporting a profit while its opponent remains loss making.
IGC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $328K | +72% |
| Q2 2026 | $265K | -19% |
| Q1 2026 | $317K | -3.9% |
| Q4 2025 | $350K | +36% |
| Q3 2025 | $191K | -54% |
| Q2 2025 | $328K | +21% |
| Q1 2025 | $330K | +12% |
| Q4 2024 | $257K | +26% |
IGC's revenue is recovering but still below its 2020 peak: $328,000 last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -589% | +929 points |
| Q2 2026 | -1051% | -470 points |
| Q1 2026 | -775% | -348 points |
| Q4 2025 | -840% | -110 points |
| Q3 2025 | -1518% | -1091 points |
| Q2 2025 | -581% | +300 points |
| Q1 2025 | -428% | +308 points |
| Q4 2024 | -731% | +739 points |
IGC's operating margin was −589% last quarter, up 929 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over IGC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over IGC on profitability, with a higher operating margin.
IGC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.4M | +$702K |
| Q2 2026 | -$1.4M | +$60K |
| Q1 2026 | -$1.2M | -$476K |
| Q4 2025 | -$1.2M | +$109K |
| Q3 2025 | -$2.1M | -$1.1M |
| Q2 2025 | -$1.4M | +$375K |
| Q4 2024 | -$1.3M | +$243K |
| Q3 2024 | -$1M | +$593K |
IGC has burned cash in almost every quarter: −$5M over the past year, against −$6M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over IGC on cash generation, producing positive trailing cash flow while its opponent burns cash.
IGC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.1% | +9.2M shares |
| 1 year | +21% | +19M shares |
| 3 years | +106% | +56.4M shares |
| 5 years | +129% | +61.6M shares |
IGC has 109M diluted shares, up 21% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over IGC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
IGC Net Leverage
IGC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
IGC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.4 | Neutral |
| Stochastic | 42.1 | Neutral |
IGC's weekly RSI is 30 (neutral) and its Stochastic is 42 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
IGC PE vs Healthcare Sector
IGC has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
IGC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.24 | 25% below |
| 20 week MA | $0.26 | 31% below |
| 50 week MA | $0.28 | 36% below |
| 100 week MA | $0.31 | 42% below |
| 200 week MA | $0.34 | 47% below |
IGC is in a downtrend: it's below all five of its weekly moving averages, and 47% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over IGC on trend strength, trading above more of its moving averages.
IGC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.61 | $1.75 | +187% |
| 2021 | $1.75 | $1.15 | -34% |
| 2022 | $1.15 | $0.34 | -70% |
| 2023 | $0.34 | $0.28 | -18% |
| 2024 | $0.28 | $0.37 | +32% |
| 2025 | $0.37 | $0.30 | -19% |
| 2026 YTD | $0.30 | $0.18 | -40% |
IGC's yearly returns have swung widely, from +187% in 2020 to −70% in 2022. It's down 40% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over IGC on returns for 2026, with the stronger performance.